Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2024 Sep 1:53:60-62.
doi: 10.1016/j.jdcr.2024.08.020. eCollection 2024 Nov.

Imatinib associated discoid lupus erythematosus in a patient with chronic myeloid leukemia

Priya Sarlashkar  1 , Christian Carr  1 , Meghan Heberton  1
Affiliations
Case Reports

Imatinib associated discoid lupus erythematosus in a patient with chronic myeloid leukemia

Priya Sarlashkar et al. JAAD Case Rep. .
No abstract available

Keywords: cutaneous toxicities; discoid lupus erythematosus; drug reaction; imatinib; oncodermatology.

PubMed Disclaimer

Conflict of interest statement

Dr Heberton has served on an advisory board for Blueprint Medicines. Authors Sarlashkar and Carr have no conflicts of interest to declare.

Figures

Fig 1
Fig 1
Hyperpigmented, scaly, violaceous patches on bilateral cheeks sparing the nasolabial folds.
Fig 2
Fig 2
Hyperpigmented, pink patches with follicular plugging in conchal bowls and scaphoid fossa.
See this image and copyright information in PMC

References

    1. Al Baghdadi T., Abonour R., Boswell H.S. Novel combination treatments targeting chronic myeloid leukemia stem cells. Clin Lymphoma Myeloma Leuk. 2012;12(2):94–105. doi: 10.1016/j.clml.2011.10.003. - DOI - PubMed
    1. Brazzelli V., Grasso V., Borroni G. Imatinib, dasatinib and nilotinib: a review of adverse cutaneous reactions with emphasis on our clinical experience. J Eur Acad Dermatol Venereol. 2013;27(12):1471–1480. doi: 10.1111/jdv.12172. - DOI - PubMed
    1. Aringer M., Costenbader K., Daikh D., et al. 2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus. Arthritis Rheumatol. 2019;71(9):1400–1412. doi: 10.1002/art.40930. - DOI - PMC - PubMed
    1. Gronhagen C.M., Fored C.M., Linder M., Granath F., Nyberg F. Subacute cutaneous lupus erythematosus and its association with drugs: a population-based matched case-control study of 234 patients in Sweden. Br J Dermatol. 2012;167(2):296–305. doi: 10.1111/j.1365-2133.2012.10969.x. - DOI - PubMed
    1. Larmonier N., Janikashvili N., LaCasse C.J., et al. Imatinib mesylate inhibits CD4+CD25+ regulatory T cell activity and enhances active immunotherapy against BCR-ABL− tumors. J Immunol. 2008;181(10):6955–6963. doi: 10.4049/jimmunol.181.10.6955. - DOI - PMC - PubMed

Publication types